ALSUntangled does not recommend apoaequorin for ALS
Original source
Apoaequorin (Prevagen) (opens in a new tab)ALSUntangled concluded that there was not enough evidence to determine whether apoaequorin, also called Prevagen, slows ALS progression. It noted that the available case series involved multiple treatments and lacked standardized outcome measurements. The group did not recommend that people with ALS take apoaequorin.
Why this matters
This means apoaequorin is not supported as an ALS treatment by this review. The evidence described is too limited to show benefit or independently confirm its safety, so this does not change treatment recommendations.
Limitations and context
This is an independent expert review from 2012, not a controlled clinical trial. The cited evidence included one small case series with methodological weaknesses, manufacturer safety information without independent systematic confirmation, and two reported serious adverse events from PatientsLikeMe members. Controlled studies or better-characterized patient studies using validated measures would still be needed.